DENTSPLY SIRONA (NASDAQ:XRAY) Releases FY 2026 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 1.200-1.300 for the period, compared to the consensus EPS estimate of 1.470. The company issued revenue guidance of $3.5 billion, compared to the consensus revenue estimate of $3.6 billion.

DENTSPLY SIRONA Stock Down 5.3%

DENTSPLY SIRONA stock traded down $0.56 during mid-day trading on Thursday, reaching $10.09. The stock had a trading volume of 7,841,624 shares, compared to its average volume of 4,909,970. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.07 and a current ratio of 1.63. DENTSPLY SIRONA has a fifty-two week low of $8.32 and a fifty-two week high of $14.76. The stock’s 50-day simple moving average is $9.65 and its 200-day simple moving average is $11.30. The firm has a market capitalization of $2.01 billion, a PE ratio of -3.67, a price-to-earnings-growth ratio of 1.25 and a beta of 0.87.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Thursday, November 5th. The medical instruments supplier reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.02). The firm had revenue of $836.00 million for the quarter, compared to analyst estimates of $861.68 million. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%. DENTSPLY SIRONA has set its FY 2026 guidance at 1.200-1.300 EPS. On average, sell-side analysts forecast that DENTSPLY SIRONA will post 1.39 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on XRAY. BMO Capital Markets dropped their target price on DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating on the stock in a report on Thursday, September 17th. Barrington Research dropped their target price on shares of DENTSPLY SIRONA from $15.00 to $13.00 and set an “outperform” rating on the stock in a research report on Monday, October 26th. Leerink Partners reduced their target price on DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating for the company in a report on Wednesday, October 14th. Barclays upped their price objective on DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a research note on Monday, August 24th. Finally, Piper Sandler decreased their price target on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Friday, October 9th. Three analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $12.62.

About DENTSPLY SIRONA

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.